U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...

U.S. Senator Maggie Hassan (D-NH) is intensifying her scrutiny of GSK Plc (NYSE:GSK) over the company's decision to pull its ...

Amid ongoing controversy, Sen. Maggie Hassan (D-N.H.) is investigating GSK for replacing a popular asthma inhaler with a ...

Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant ...

Democratic U.S. Senator Maggie Hassan has reportedly launched an investigation into British pharmaceutical giant GSK's (NYSE:GSK) decision to pull the branded Flovent HFA asthma inhaler from the U.S.

Pharmaceutical manufacturer GlaxoSmithKline (GSK) announced that as of Jan. 1 it would no longer produce the asthma inhaler Flovent, one of the most popular preventive and maintenance treatments ...

As of Jan. 1, thousands of asthma patients in the U.S. will no longer be able to get refills for Flovent — one of the most popular inhalers in the U.S. for nearly 30 years. Flovent’s ...

Medicaid spent an estimated $551.8 million in 2024 on GSK’s authorized generic inhaler, nearly double the expected cost with Flovent HFA. Hospitalizations for asthma spiked 24.1% in the six ...

Flovent — a common asthma inhaler — will be discontinued in 2024. There will be a generic version available, but the change could make it hard for some patients to get their medication.

Glaxo Smith Kline (GSK) announced in May that Flovent HFA, a metered-dose inhaler, as well as Flovent Diskus, a dry powder inhaler, would be discontinued as of Dec. 31, 2023. Experts weigh in.

Flovent, a popular asthma inhaler, will no longer be available in pharmacies as of January 1, ... 2024, GlaxoSmithKline will stop manufacturing Flovent HFA and Flovent Diskus.

GSK (GSK) faces an investigation from U.S. Senator Maggie Hassan over its decision to discontinue Flovent HFA asthma inhaler last year. Read more here.